MDxHealth S.A.
NASDAQ:MDXHMedical - Diagnostics & Research
-$0.03 today
- Market cap
- $57.59M
- Beta
- 0.38
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$0.58
Volume 0.65M
Average 4.27M
MDXH Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
MDxHealth S.A.NASDAQ: MDXH
Other Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Other current liabilities falls 24.1% from a year ago
Other current liabilities stood at $25.03M at the end of Q2 FY2026, down 24.1% from a year earlier. Over 3 fiscal years it compounded at +152.2% a year.
Context
- Other current liabilities amounted to 18.9% of total assets at the end of Q2 FY2026, down 4.5 pp from a year earlier.
- Other current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps falling in the next quarterly balance sheet after a -24.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 37.31M USD
- Year-over-year change
- +41.3%
- 4-year CAGR
- +149.6%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 37.31M | +41.3% |
| FY2024 | 2024-12-31 | 26.41M | +812.3% |
| FY2023 | 2023-12-31 | 2.9M | +24.4% |
| FY2022 | 2022-12-31 | 2.33M | +142.1% |
| FY2021 | 2021-12-31 | 961K | — |
Other Current Liabilities vs competitors
How MDXH compares with its peers on the latest reported figures
- MDXH's Jun 2026 other current liabilities of $25.03M is the 2nd highest of the 11 companies compared; the peer median is $5.66M.
- Its year-over-year change of -24.1% is the 7th highest of 10, against a peer median of +29.6%.
- Other current liabilities amounts to 18.9% of total assets for MDXH, versus a peer median of 2.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.11B | +304928.8% | +7.5% | 1.4% | |
| Jun 2026 | $25.03M | -24.1% | +152.2% | 18.9% | |
| Mar 2026 | $9.85M | +56.2% | +25.6% | 2.7% | |
| Mar 2026 | $9.1M | -35.3% | -47.4% | 24.5% | |
| Mar 2026 | $6.37M | +44.9% | — | 4.0% | |
| Mar 2026 | $6.06M | -39.9% | -8.8% | 3.0% | |
| Mar 2026 | $5.27M | -12.4% | +210.8% | 9.7% | |
| Mar 2026 | $4.77M | — | +142.3% | 9.2% | |
| Mar 2026 | $2.37M | +29.6% | +132.4% | 1.0% | |
ZURAZura Bio Limited | Mar 2026 | $1.13M | +57.7% | +6.1% | 0.5% |
| Jun 2026 | $0 | -100.0% | +58.9% | 0.0% | |
| Peer median (excluding MDXH) | $5.66M | +29.6% | +25.6% | 2.9% | |
Competitors are the stored peer set for MDXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 58.5M | 15.5M | 22.38M | 46.8M | 29.03M |
| Short-term Investments | 89K | 101K | 0 | 0 | 0 |
| Net Receivables | 4.58M | 9.36M | 11.27M | 14.53M | 14.73M |
| Inventory | 1.91M | 2.33M | 2.78M | 3.87M | 6.74M |
| Other Current Assets | 504K | 151K | 146K | 135K | 940K |
| Total Current Assets | 66.61M | 29.15M | 38.16M | 66.9M | 53.41M |
| Property, Plant & Equipment (Net) | 5.02M | 7.89M | 9.95M | 12.98M | 14.68M |
| Goodwill | 0 | 35.93M | 35.93M | 35.93M | 38.95M |
| Intangible Assets | 3.45M | 46.17M | 44.34M | 40.59M | 39.42M |
| Long-term Investments | 0 | 0 | 763K | 936K | 1.5M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 8.47M | 89.99M | 90.97M | 90.43M | 94.54M |
| Total Assets | 75.07M | 119.14M | 129.13M | 157.33M | 147.95M |
| Account Payables | 7.46M | 10.18M | 8.81M | 8M | 10.33M |
| Short-term Debt | 4.44M | 616K | 643K | 324K | 1.9M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 472K | 0 | 0 |
| Other Current Liabilities | 961K | 2.33M | 2.9M | 26.41M | 37.31M |
| Total Current Liabilities | 16.43M | 18.28M | 19.52M | 42.66M | 49.53M |
| Long-term Debt | 7.65M | 34.91M | 35.56M | 50.97M | 84.71M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 1.47M | 53.54M | 63.26M | 41.45M | 17.3M |
| Total Non-current Liabilities | 11.74M | 91.54M | 102.4M | 99.83M | 110.51M |
| Total Liabilities | 28.17M | 109.82M | 121.92M | 142.49M | 160.05M |
| Common Stock | 143.42M | 148.42M | 173.93M | 214.67M | 219.21M |
| Retained Earnings | (244.3M) | (288.35M) | (331.45M) | (369.52M) | (403.03M) |
| Accumulated OCI | (5.4M) | (3.94M) | 11.55M | (615K) | 18.55M |
| Other Stockholders Equity | 0 | 0 | 0 | 17.12M | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 46.9M | 9.32M | 7.21M | 14.84M | (12.09M) |
| Total Debt | 15.56M | 39.79M | 41.27M | 60.06M | 95.11M |
| Net Debt | (42.94M) | 24.29M | 18.89M | 13.27M | 66.08M |
MDxHealth S.A.
NASDAQ:MDXH
Intrinsic Alpha fair value
Locked
Current Price
$0.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.